Skip to main content

Home/ Dr. Goodyear/ Group items tagged Hodgkin's disease

Rss Feed Group items tagged

Nathan Goodyear

In-vitro sensitivity of Hodgkin's disease to hydrogen peroxide toxicity. Correlation wi... - 0 views

  •  
    small study of cells from patients with Hodgkin's disease found that hydrogen peroxide therapy increased cell sensitization to cytotoxicity of nodular and mixed Hodgkin's disease to 
Nathan Goodyear

Rare Occurrence of 3 "H": Hypercalcemia, Hemolytic Anemia and Hodgkin's Lymphoma - 0 views

  • administered zoledronic acid (4 mg). Prednisolone (1 mg/kg/day) was started and simultaneously, she was administered first cycle of ABVD (Adriamycin: 25 mg/m2, Bleomycin: 10 U/m2, Vinblastine: 6 mg/m2 and Dacarbazine: 375 mg/m2), which led to normalisation of serum calcium levels over 4 days and improvement in her hemoglobin levels
  • Etiology of anemia in Hodgkin’s lymphoma is multifactorial. Anemia of chronic disease, decreased red cell survival, infiltration of bone marrow by tumor and marrow suppression by chemotherapy/radiotherapy are the common mechanisms
  • Our case had only a transient response to steroids and chemotherapy. Therefore, she was treated with Rituximab which brought hemolysis under control
  • ...7 more annotations...
  • Mechanism of hypercalcemia in HL has long been suggested to involve extra-renal activation of 1α-hydroxylase leading to production of 1, 25(OD)2 Vitamin D3 or Calcitriol, an active metabolite of Vitamin D, which leads to increased re-absorption of calcium and phosphate from intestine, increased osteoclast activation and bone resorption as well as increased phosphate re-absorption in renal tubules
  • Hypercalcemia of malignancy involves three mechanisms: 1. Humoral hypercalcemia mediated by PTHrP—seen in solid tumors like breast cancer and adult T cell leukemia/lymphoma (ATLL), 2. Direct osteoclast mediated bone resorption due to bony metastasis—seen in solid tumors and multiple myeloma, 3. Calcitriol mediated hypercalcemia—seen in Hodgkin’s and non-Hodgkin’s lymphoma as well as granulomatous disorders like tuberculosis, sarcoidosis, leprosy and disseminated Candidiasis
  • Hypercalcemia in HL is rare and its incidence has been reported as 0.9, 1.6 and 5.4 % in different series
  • The source of 1α-hydroxylase in HL has been postulated as monocytes and macrophages infiltrating the tumor akin to tuberculosis or sarcoidosis and is stimulated by IFN-γ secreted by T-lymphocytes
  • Like sarcoidosis, patients with HL exhibit increased sensitivity to Vitamin D supplements and sunlight, which have been found to precipitate hypercalcemia in these patients
  • Classical biochemical profile in Calcitriol mediated hypercalcemia include: an elevated calcium, normal/slightly elevated phosphate, normal 25(OH) Vitamin D, suppressed PTHrP and PTH, elevated Calcitriol and a normal/increased tubular reabsorption of phosphate
  • not been associated with a poorer prognosis and tends to subside after treatment of the underlying disease
  •  
    great read on hypercalcemia in hodgkin's lymphoma.
Nathan Goodyear

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblasti... - 0 views

  •  
    monoclonal Ab used in sequence with AVD found to have event-free survival, progression-free survival, and overal survival rates of 80%, 84%, and 93% respectively in older adults with Hodgkin's lymphoma.
Nathan Goodyear

https://www.scipress.com/IJPPE.8.1.pdf - 0 views

  •  
    Great article out of romania on liver involvment in lymphoma.
Nathan Goodyear

The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of... - 0 views

  •  
    Thymidine kinase 1 useful as a prognostic biomarker and to monitor therapy efficacy. TK-1 levels were very low in those without cancer. Higher TK-1 levels pretreatment were associated with poor prognosis and poor survival. TK-1 "increases with progress of the disease, decreases during successful therapy, and finally increases during relapse.
Nathan Goodyear

A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal ... - 0 views

  •  
    Abstract only here.  Immunotherapy of IL-2 + melatonin provided lack of progression of 67% of patients included with a average duration of 21+ months in patients with untreatable advanced hematologic cancer.  Again, no toxicities.  Interesting, the survival time was similar to the previously reported survival times with the highly toxic high dose IL-2 therapy.
1 - 6 of 6
Showing 20 items per page